Haugen / Norvell v. Oregon Health Authority
Oregon court ruling may restrict scope of practice for non-physician practitioners in med spas, requiring closer supervision or revised protocols.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 8, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Nurse-owned and multi-location med spas in Oregon should confirm how it applies to their specific situation before acting. There is a time constraint attached: 30 days. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Med-Spa & Aesthetics Clinics move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Court decision potentially limits injectable and laser procedures by NPs/RNs without direct physician oversight.
Who it affects
Nurse-owned and multi-location med spas in Oregon
What you must do
Review current supervision agreements and scope of practice protocols; consult legal counsel.
Deadline
30 days
Source: https://www.courtlistener.com/opinion/10854188/haugen-norvell-v-oregon-health-authority/
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- Beauty Lab and Laser v. Fowler
- Smith v. Upper Chesapeake Medical Ctr.
- Regulatory Considerations for Microneedling Products; Guidance for Industry and Food and Drug Administration Staff; Availability
- Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab